TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Central Venous Catheter Infections : Comparison of the Efficacy of Skin Disinfection With 5% Povidone Iodine in Alcoholic Solution Versus 0.25% Chlorhexidine, 0.025 Benzalkonium and 4% Benzylic Alcohol
Brief Summary: The best antiseptic solution for cateheter care remains unknown.High concentration in aquous solution or low concentration in alcoholic solution of chlorhexidine actbetter than povidone iodine in aquous solutions. No study has compare alcoholic formulations of low concentration of chlorhexidine and povidone iodine for skin disinfection prior to insertion of central venous catheters.

To compare the incidence of central venous catheter colonization after skin disinfection with either an alcoholic solution of povidone iodine or a combination of 0.5% chlorhexidine, 0.025% Benzalkonium and 4% benzylic alcohol.

To compare the incidence of catheter related bacteremia in the to study groups. To compare the local and general tolerance of the two antiseptic formulations


Options:
A: Arm Label: 3-days dressing frequency/CHX sponge; Type: EXPERIMENTAL; Interventions: Device: Chlorhexidine Sponge (Biopatch TM) | Arm Label: 7-days dressing frequency/CHX sponge; Type: EXPERIMENTAL; Interventions: Device: Chlorhexidine Sponge (Biopatch TM), Behavioral: 7-day catheter dressing frequency | Arm Label: 3-days dressing frequency/No CHX sponge; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 7-days dressing change/No CHX sponge; Type: EXPERIMENTAL; Interventions: Behavioral: 7-day catheter dressing frequency | Intervention Type: DEVICE; Name: Chlorhexidine Sponge (Biopatch TM); Assigned to Arm(s): 3-days dressing frequency/CHX sponge, 7-days dressing frequency/CHX sponge | Intervention Type: BEHAVIORAL; Name: 7-day catheter dressing frequency; Assigned to Arm(s): 7-days dressing change/No CHX sponge, 7-days dressing frequency/CHX sponge
B: Intervention Type: DRUG; Name: Skin disinfection; Assigned to Arm(s): N/A
C: Arm Label: Oct/Alc; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.1% Octenidine with 30% 1-propanol and 45% 2-propanol | Arm Label: Alc; Type: ACTIVE_COMPARATOR; Interventions: Drug: 74% Ethanol with 10% 2-propanol | Intervention Type: DRUG; Name: 0.1% Octenidine with 30% 1-propanol and 45% 2-propanol; Assigned to Arm(s): Oct/Alc | Intervention Type: DRUG; Name: 74% Ethanol with 10% 2-propanol; Assigned to Arm(s): Alc
D: Arm Label: PVI paint; Type: ACTIVE_COMPARATOR; Interventions: Procedure: skin disinfection prior catheter insertion | Arm Label: PVI scrub and paint; Type: ACTIVE_COMPARATOR; Interventions: Procedure: skin disinfection prior catheter insertion | Arm Label: Chlorhexidine paint; Type: ACTIVE_COMPARATOR; Interventions: Procedure: skin disinfection prior catheter insertion | Arm Label: chlorhexidine scrub and paint; Type: ACTIVE_COMPARATOR; Interventions: Procedure: skin disinfection prior catheter insertion | Intervention Type: PROCEDURE; Name: skin disinfection prior catheter insertion; Assigned to Arm(s): Chlorhexidine paint, PVI paint, PVI scrub and paint, chlorhexidine scrub and paint

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: American-Australian-African Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm (ADONIS)
Brief Summary: To assess the efficacy of dronedarone versus placebo for the maintenance of normal sinus rhythm after electrical, pharmacological or spontaneous conversion of atrial fibrillation/atrial flutter (AF/AFL).

To assess the efficacy of dronedarone versus placebo on ventricular rate control in case of AF/AFL recurrence.

To assess the efficacy of dronedarone versus placebo on AF/AFL-related symptoms.


Options:
A: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: Dronedarone (SR33589) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Drug Treatment; Type: ACTIVE_COMPARATOR; Interventions: Device: Radiofrequency ablation, antiarrhythmic drugs, Drug: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs | Arm Label: ThermoCool Radiofrequency Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Radiofrequency ablation, antiarrhythmic drugs, Device: ThermoCool Radiofrequency Catheter | Intervention Type: DEVICE; Name: Radiofrequency ablation, antiarrhythmic drugs; Assigned to Arm(s): Drug Treatment, ThermoCool Radiofrequency Catheter | Intervention Type: DRUG; Name: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs; Assigned to Arm(s): Drug Treatment | Intervention Type: DEVICE; Name: ThermoCool Radiofrequency Catheter; Assigned to Arm(s): ThermoCool Radiofrequency Catheter
C: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: Dronedarone (SR33589) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: NAVISTAR® THERMOCOOL® Catheter; Type: EXPERIMENTAL; Interventions: Device: NAVISTAR® THERMOCOOL® Catheter | Arm Label: Antiarrhythmic drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiarrhythmic drug | Intervention Type: DEVICE; Name: NAVISTAR® THERMOCOOL® Catheter; Assigned to Arm(s): NAVISTAR® THERMOCOOL® Catheter | Intervention Type: DRUG; Name: Antiarrhythmic drug; Assigned to Arm(s): Antiarrhythmic drug

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: American-Australian-African Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm (ADONIS)
Brief Summary: To assess the efficacy of dronedarone versus placebo for the maintenance of normal sinus rhythm after electrical, pharmacological or spontaneous conversion of atrial fibrillation/atrial flutter (AF/AFL).

To assess the efficacy of dronedarone versus placebo on ventricular rate control in case of AF/AFL recurrence.

To assess the efficacy of dronedarone versus placebo on AF/AFL-related symptoms.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% saline | Arm Label: Antazoline; Type: EXPERIMENTAL; Interventions: Drug: antazoline | Intervention Type: DRUG; Name: antazoline; Assigned to Arm(s): Antazoline | Intervention Type: DRUG; Name: 0.9% saline; Assigned to Arm(s): Placebo
B: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: Dronedarone (SR33589) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: CELIVARONE (SSR149744C); Assigned to Arm(s): N/A
D: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: dronedarone (SR33589) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: EURopean Trial In Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)
Brief Summary: To assess the efficacy of dronedarone versus placebo for the maintenance of normal sinus rhythm after electrical, pharmacological or spontaneous conversion of atrial fibrillation/atrial flutter (AF/AFL).

To assess the efficacy of dronedarone versus placebo on AF/AFL-related symptoms.

To assess the efficacy of dronedarone versus placebo on ventricular rate control in case of AF/AFL recurrence.


Options:
A: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: Dronedarone (SR33589) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Intervention Type: PROCEDURE; Name: Circumferential Pulmonary Vein Ablation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Antiarrhythmic Drug Therapy; Assigned to Arm(s): N/A
C: Arm Label: Drug Treatment; Type: ACTIVE_COMPARATOR; Interventions: Device: Radiofrequency ablation, antiarrhythmic drugs, Drug: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs | Arm Label: ThermoCool Radiofrequency Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Radiofrequency ablation, antiarrhythmic drugs, Device: ThermoCool Radiofrequency Catheter | Intervention Type: DEVICE; Name: Radiofrequency ablation, antiarrhythmic drugs; Assigned to Arm(s): Drug Treatment, ThermoCool Radiofrequency Catheter | Intervention Type: DRUG; Name: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs; Assigned to Arm(s): Drug Treatment | Intervention Type: DEVICE; Name: ThermoCool Radiofrequency Catheter; Assigned to Arm(s): ThermoCool Radiofrequency Catheter
D: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: Dronedarone (SR33589) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: EURopean Trial In Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)
Brief Summary: To assess the efficacy of dronedarone versus placebo for the maintenance of normal sinus rhythm after electrical, pharmacological or spontaneous conversion of atrial fibrillation/atrial flutter (AF/AFL).

To assess the efficacy of dronedarone versus placebo on AF/AFL-related symptoms.

To assess the efficacy of dronedarone versus placebo on ventricular rate control in case of AF/AFL recurrence.


Options:
A: Intervention Type: PROCEDURE; Name: Circumferential Pulmonary Vein Ablation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Antiarrhythmic Drug Therapy; Assigned to Arm(s): N/A
B: Arm Label: Propafenone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propafenone | Arm Label: Dronedarone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dronedarone | Intervention Type: DRUG; Name: Propafenone; Assigned to Arm(s): Propafenone | Intervention Type: DRUG; Name: Dronedarone; Assigned to Arm(s): Dronedarone
C: Intervention Type: DRUG; Name: CELIVARONE (SSR149744C); Assigned to Arm(s): N/A
D: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: Dronedarone (SR33589) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Radiocontrast Media Induced Nephropathy by Short-Term High-Dose Statin in Renal Insufficiency Undergoing Coronary Angiography (PROMISS)
Brief Summary: The contrast induced kidney toxicity has been known to affect the mortality and morbidity in the patients undergoing coronary angiography. But the mechanism and therapeutic strategy for it is not well known. Nowadays, it is reported that the N-acetylcysteine may have preventive effects for contrast induced kidney toxicity with its antioxidant effects.The statins have been reported to have many other effects other than the lipid lowering effect-including antioxidant effect, so we hypothesized that the antioxidant effect of simvastatin may prevent the contrast induced kidney toxicity.


Options:
A: Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A
B: Arm Label: Rosuvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin
C: Arm Label: treatment; Type: EXPERIMENTAL; Interventions: Drug: Simvastatin | Arm Label: untreated; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): treatment
D: Arm Label: On Pump Arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Coronary Artery Bypass Graft with the use of CPB | Arm Label: Off Pump Arm; Type: EXPERIMENTAL; Interventions: Procedure: Coronary Artery Bypass Graft without the use of CPB | Intervention Type: PROCEDURE; Name: Coronary Artery Bypass Graft with the use of CPB; Assigned to Arm(s): On Pump Arm | Intervention Type: PROCEDURE; Name: Coronary Artery Bypass Graft without the use of CPB; Assigned to Arm(s): Off Pump Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Managing Problem Behaviors of Alzheimer's Disease
Brief Summary: This study tests the effectiveness of an in-home intervention to reduce upset and burden among family caregivers, and decrease nursing home placement. The main hypothesis that will be tested is that compared to control group, subjects, experimental group participants will have enhanced well-being and fewer nursing home placements.


Options:
A: Arm Label: Tailored Activity Program; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored Activity Program | Arm Label: Home Safety and Education Program; Type: ACTIVE_COMPARATOR; Interventions: Other: Home Safety and Education Program | Intervention Type: BEHAVIORAL; Name: Tailored Activity Program; Assigned to Arm(s): Tailored Activity Program | Intervention Type: OTHER; Name: Home Safety and Education Program; Assigned to Arm(s): Home Safety and Education Program
B: Intervention Type: BEHAVIORAL; Name: In-home intervention; Assigned to Arm(s): N/A
C: Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: COPE plus usual care; Type: EXPERIMENTAL; Interventions: Behavioral: Care of Persons with Dementia in their Environments | Intervention Type: BEHAVIORAL; Name: Care of Persons with Dementia in their Environments; Assigned to Arm(s): COPE plus usual care
D: Arm Label: active tDCS plus real CT; Type: EXPERIMENTAL; Interventions: Device: active tDCS, Behavioral: real CT | Arm Label: sham tDCS plus real CT; Type: EXPERIMENTAL; Interventions: Device: sham tDCS, Behavioral: real CT | Arm Label: active tDCS plus placebo CT; Type: EXPERIMENTAL; Interventions: Device: active tDCS, Behavioral: placebo CT | Arm Label: sham tDCS plus placebo CT; Type: PLACEBO_COMPARATOR; Interventions: Device: sham tDCS, Behavioral: placebo CT | Intervention Type: DEVICE; Name: active tDCS; Assigned to Arm(s): active tDCS plus placebo CT, active tDCS plus real CT | Intervention Type: DEVICE; Name: sham tDCS; Assigned to Arm(s): sham tDCS plus placebo CT, sham tDCS plus real CT | Intervention Type: BEHAVIORAL; Name: real CT; Assigned to Arm(s): active tDCS plus real CT, sham tDCS plus real CT | Intervention Type: BEHAVIORAL; Name: placebo CT; Assigned to Arm(s): active tDCS plus placebo CT, sham tDCS plus placebo CT

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tailored Activity to Improve Affect in Dementia
Brief Summary: Specific Aims

1. Establish a preliminary effect size for the impact of the intervention on depressive affect and agitated behaviors in persons with dementia in 4 months
2. Evaluate acceptance of and engagement in activities in persons with dementia
3. Establish a preliminary effect size for the impact of the intervention on caregiver burden, depressive symptoms, and mastery at 4 months.
4. Evaluate caregiver skills acquisition, acceptance of and compliance to intervention techniques.


Options:
A: Arm Label: Tailored Activity Program; Type: EXPERIMENTAL; Interventions: Other: Tailored Activity Program | Arm Label: Attention Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Attention Control | Intervention Type: OTHER; Name: Tailored Activity Program; Assigned to Arm(s): Tailored Activity Program | Intervention Type: OTHER; Name: Attention Control; Assigned to Arm(s): Attention Control
B: Arm Label: Tailored Activity Program; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored Activity Program | Arm Label: Home Safety and Education Program; Type: ACTIVE_COMPARATOR; Interventions: Other: Home Safety and Education Program | Intervention Type: BEHAVIORAL; Name: Tailored Activity Program; Assigned to Arm(s): Tailored Activity Program | Intervention Type: OTHER; Name: Home Safety and Education Program; Assigned to Arm(s): Home Safety and Education Program
C: Intervention Type: BEHAVIORAL; Name: Home-Based Behavorial Intervention; Assigned to Arm(s): N/A
D: Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: COPE plus usual care; Type: EXPERIMENTAL; Interventions: Behavioral: Care of Persons with Dementia in their Environments | Intervention Type: BEHAVIORAL; Name: Care of Persons with Dementia in their Environments; Assigned to Arm(s): COPE plus usual care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)
Brief Summary: The purpose of this study is to 1)to determine if it is better to treat all early RA patients with methotrexate in combination with hydroxychloroquine plus sulfasalazine or in combination with etanercept or reserve this treatment for patients who do not appropriately respond to methotrexate alone and 2) to determine which combination of methotrexate therapy is better


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: etanercept | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: sulfasalazine, Drug: hydroxychloroquine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: etanercept | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: sulfasalazine, Drug: hydroxychloroquine | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: sulfasalazine; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: hydroxychloroquine; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1, 3
B: Arm Label: Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab
C: Arm Label: Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Arm Label: Sequence 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 4 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 4
D: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)
Brief Summary: The purpose of this study is to 1)to determine if it is better to treat all early RA patients with methotrexate in combination with hydroxychloroquine plus sulfasalazine or in combination with etanercept or reserve this treatment for patients who do not appropriately respond to methotrexate alone and 2) to determine which combination of methotrexate therapy is better


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept , Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide | Intervention Type: DRUG; Name: Etanercept , Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide; Assigned to Arm(s): 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: etanercept | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: sulfasalazine, Drug: hydroxychloroquine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: etanercept | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: sulfasalazine, Drug: hydroxychloroquine | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: sulfasalazine; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: hydroxychloroquine; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1, 3
C: Arm Label: Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1

Answer: B